SOLACI | Latin American Society of Interventional Cardiology

Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected.

Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system.

PCI is often used at present to treat heart disease, and some of these patients present ID. Different analysis suggest that PCI might evolve differently vs. patients with no ID; however, it has not yet been thoroughly looked into.

There was a retrospective analysis, from January 2016 to December 2020, including 2,360,860 patients; 7,855 (0.77%) with ID (amyloidosis 990, sarcoidosis 5,260 and hemochromatosis 1,625).

Primary end point was the post-PCI combination of inhospital death, stroke and major bleeding.

Patients with amyloidosis were older and had more comorbidities vs. sarcoidosis and hemochromatosis patients.

Primary end point resulted more frequent in amyloidosis patients (1.6% vs. 1.1% vs. 1.18%, OR 1.6; CI del 95%, 1.1-2.44; P= .02 for amyloidosis, sarcoidosis and hemochromatosis, respectively); they also showed higher mortality (1.9% vs. 1.09% vs. 0.72%, P<0.05), and stroke (4% vs. 0% vs. 2.28%, P<0.05), but there were no significant differences in major bleeding (2.2% vs. 0.96% vs. 1.03%, p>0.05).

The cost of hospitalization and hospital stay was higher in patients with amyloidosis.

Conclusion

Amyloidosis was associated with worse evolution after PCI, including higher inhospital mortality, intra and post procedural stroke, and socioeconomic cost. We highlight the need for a multidisciplinary approach for better assessment and further research, to better guide the screening and management strategy of these patients.